[A pilot study of intraperitoneal gemcitabine for reduction of peritoneal dissemination in advanced pancreatic cancer].
We schemed intraperitoneal gemcitabine (ipGEM) for reduction of peritoneal dissemination to three patients with unresectable and one patient with recurrent pancreatic cancer, followed by intraperitoneal catheter and subcutaneous port placement. Two locally advanced cases were performed for intra-operative radiotherapy, and one of 2 locally advanced cases was performed for gastrojejunostomy. And another locally advanced case had ileostomy. The recurrent case was resected for metastatic tumor of abdominal wall. In one of locally advanced cases, we couldn't perform ipGEM for progression of disease. In two remaining locally advanced cases, we could keep on doing ipGEM, and the patients did not experience with abdominal discomfort or hematological toxicity.
Dept. of Surgery, Kurume University School of Medicine.
Hiroyuki
H
Horiuchi
Hidefumi
H
Nogita
Yusuke
Y
Kawashima
Yuhei
Y
Kitazato
Masakane
M
Akashi
Gen
G
Akasu
Kazuhiro
K
Mikagi
Ryuichi
R
Kawahara
Hiroto
H
Ishikawa
Tohru
T
Hisaka
Hisafumi
H
Kinoshita
Kazuo
K
Shirouzu
Yoshinobu
Y
Okabe
D000368:Aged; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D010865:Pilot Projects; D000093542:Gemcitabine
D003841:Deoxycytidine; D000093542:Gemcitabine